Shopping Cart
- Remove All
Your shopping cart is currently empty
FzM1.8
🥰Excellent
Catalog No. T15363Cas No. 2204290-85-5
FzM1.8 is an allosteric FZD4 agonist with a pEC50 of 6.4. FzM1.8 binds to FZD4, promotes TCF/LEF transcriptional activity in the absence of any WNT ligand, and activates the WNT/β-catenin pathway.
FzM1.8
🥰Excellent
Purity: 100%
Catalog No. T15363Cas No. 2204290-85-5
FzM1.8 is an allosteric FZD4 agonist with a pEC50 of 6.4. FzM1.8 binds to FZD4, promotes TCF/LEF transcriptional activity in the absence of any WNT ligand, and activates the WNT/β-catenin pathway.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $38 | In Stock | |
| 5 mg | $88 | In Stock | |
| 10 mg | $139 | In Stock | |
| 25 mg | $289 | In Stock | |
| 50 mg | $475 | In Stock | |
| 100 mg | $737 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $96 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "FzM1.8"
KY-05009
Cited
T117931228280-29-2
KY-05009 is a chemical compound that effectively suppresses TGF-β1-induced epithelial-to-mesenchymal transition (EMT) in human lung adenocarcinoma cells, reduces TNIK protein expression and the transcriptional activity of Wnt target genes, and promotes apoptosis in cancer cells, displaying anti-cancer properties. Furthermore, it functions as an ATP-competitive Traf2- and Nck-interacting kinase (TNIK) inhibitor with a Ki of 100 nM.
- $43
Size
QTY
CitedCHIR-99021
Cited
Laduviglusib, CT99021, CHIR-99021
T2310252917-06-9
CHIR-99021 (CT99021) is an activator of the Wnt/β-catenin signaling pathway and a GSK-3α/β inhibitor (IC50=10/6.7 nM) with selective and oral activity.CHIR-99021 induces cellular autophagy, which enhances self-renewal in mouse and human embryonic stem cells.
- $36
Size
QTY
CitedWnt pathway activator 1
T172561360540-81-3
Wnt pathway activator 1 is a potent Wnt activator with an IC50 of 28-29 nM. Wnt pathway activator 1 is a potent Wnt activator for the treatment of androgenetic alopecia (AGA).
- $29
Size
QTY
EMT inhibitor-1
T111901638526-21-2
EMT inhibitor-1 is a compound that inhibits Hippo and Wnt signaling pathways, as well as TGF- macrophages (TGF-), exhibiting antitumor activity.
- $113
Size
QTY
XAV-939 Cited
XAV939, NVP-XAV939
T1878284028-89-3
XAV-939 (NVP-XAV939) is a Tankyrase (TNKS) inhibitor that inhibits TNKS1 and TNKS2 (IC50=11/4 nM). XAV-939 selectively inhibits Wnt/β-catenin-mediated transcription.
- $48
Size
QTY
CitedTNIK-IN-2
T95572754265-76-2In house
TNIK-IN-2 is an inhibitor Traf2- and Nck-interacting protein kinase (TNIK, IC50 = 1.33 μM)) which is a downstream signal protein of the Wnt/β-catenin pathway.
- $89
Size
QTY
Bisdemethoxycurcumin
Didemethoxycurcumin, Curcumin III
TL000724939-16-0
Bisdemethoxycurcumin (Curcumin III) is a natural demethoxy derivative of curcumin. It is a potent activator of macrophage phagocytosis, interacting with 1α, 25-dihydroxy vitamin D3 to stimulate amyloid-β clearance by macrophages (optimal stimulation at 100 nM BDMC) [1]. More stable than curcumin in physiological media, BDMC suppresses proliferation of cancer cells [2]. It down-regulates the transcriptional coactivator p300, suppressing the Wnt/β-catenin pathway, and inhibits LPS induction of iNOS expression [3].
- $31
Size
QTY
PRI-724
Foscenvivint, C-82 prodrug
T644141422253-38-0
PRI-724 is a second-generation, selective small molecule inhibitor of the β-catenin/CBP interaction.
- $42
Size
QTY
L-quebrachitol
T5729642-38-6
L-quebrachitol is a natural product.L-quebrachitol may promote osteoblastogenesis by triggering the BMP-2-response as well as the Runx2, MAPK, and Wnt/β-catenin signaling pathway.
- $31
Size
QTY
Urea
Ureophil, E-Cardamoni, Carbonyldiamide, Carbamide
T073857-13-6
Urea (Carbonyldiamide) is formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end metabolite of protein catabolism and accounts for about one-half of the total urinary solids.
- $30
Size
QTY
Nefopam hydrochloride
Nefopam HCl, Fenazoxine hydrochloride
T047023327-57-3
Nefopam hydrochloride (Nefopam HCl) is the hydrochloride salt form of nefopam, a centrally-acting, non-opioid benzoxazocine with analgesic activity.
- $37
Size
QTY
TNIK-IN-3
T95562754265-25-1In house
TNIK-IN-3 is a highly potent and orally active inhibitor of Traf2- and Nck-interacting protein kinase (TNIK). It exhibits a strong selectivity for TNIK with an IC50 value of 0.026 μM. Additionally, TNIK-IN-3 demonstrates inhibitory activity against Flt4 (IC50 = 0.030 μM), Flt1 (IC50 = 0.191 μM), and DRAK1 (IC50 = 0.411 μM). This compound holds potential for carrying out research on colorectal cancer (CRC) [1].
- $108
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | FzM1.8 is an allosteric FZD4 agonist with a pEC50 of 6.4. FzM1.8 binds to FZD4, promotes TCF/LEF transcriptional activity in the absence of any WNT ligand, and activates the WNT/β-catenin pathway. |
| Targets&IC50 | Fzm1.8:（pEC50）6.4 |
| Molecular Weight | 322.31 |
| Formula | C18H14N2O4 |
| Cas No. | 2204290-85-5 |
| Smiles | OC(=O)c1cc(O)cc(NC(=O)Nc2ccc3ccccc3c2)c1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 76.5 mg/mL (237.3 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Sci Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy FzM1.8 | purchase FzM1.8 | FzM1.8 cost | order FzM1.8 | FzM1.8 chemical structure | FzM1.8 formula | FzM1.8 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.